uniQure N.V. (QURE): who owns it and who trades it
As of Nov 16, 2026, QURE insiders reported 48 open-market sales worth $20M and no purchases in the last 12 months, with 90% of the sale value made under pre-set 10b5-1 plans. The largest seller was Matthew C Kapusta (CEO), with $12.9M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling uniQure
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns QURE
255 funds and institutions reported QURE shares worth $3.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Avoro Capital Advisors LLC with 10.7%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6.73M | 10.67% | $310M | +13% |
| JPMorgan Chase & Co | 4.87M | 7.72% | $231M | – |
| Rtw Investments, LP | 3.94M | 6.25% | $182M | +52% |
| State Street Corp | 2.90M | 4.60% | $134M | +28% |
| Aberdeen Group plc | 2.85M | 4.52% | $131M | -46% |
| California State Teachers Retirement System | 2.42M | 3.84% | $52.6M | – |
| BlackRock, Inc. | 1.88M | 2.98% | $86.5M | +8% |
| Orbimed Advisors LLC | 1.81M | 2.87% | $83.3M | -15% |
| Jane Street Group, LLC | 1.61M | 2.55% | $74.2M | +153% |
| Jennison Associates LLC | 1.56M | 2.48% | $71.9M | +27% |
| Boxer Capital Management, LLC | 1.50M | 2.38% | $69.2M | +127% |
| Goldman Sachs Group Inc | 1.48M | 2.34% | $68M | +17% |
| Two Sigma Investments, LP | 1.46M | 2.32% | $67.3M | -45% |
| Two Seas Capital LP | 1.44M | 2.29% | $66.4M | +11% |
| FMR LLC (Fidelity) | 1.27M | 2.01% | $58.5M | -27% |
| Mak Capital One LLC | 1.23M | 1.95% | $56.7M | +179% |
| Mpm Bioimpact LLC | 1.23M | 1.94% | $56.5M | -10% |
| Morgan Stanley | 1.07M | 1.69% | $49.1M | +191% |
| Assenagon Asset Management S.A. | 1.03M | 1.63% | $47.3M | +600% |
| Vestal Point Capital, LP | 935,000 | 1.48% | $43.1M | +160% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, QURE insiders reported $0 of open-market purchases and $20M of sales. 90% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 6, 2026 | David D. Meek | Director | Sale plan | 9,080 | $21.25 | $193K | Form 4 |
| Jul 2, 2026 | Matthew C Kapusta | CEO | Sale plan | 7,600 | $45.89 | $349K | Form 4 |
| Jul 2, 2026 | Matthew C Kapusta | CEO | Sale plan | 4,282 | $45.43 | $195K | Form 4 |
| Jul 2, 2026 | Matthew C Kapusta | CEO | Sale plan | 9,200 | $44.43 | $409K | Form 4 |
| Jun 30, 2026 | Walid Abi-Saab | Chief Medical Officer | Sale plan | 20,000 | $46.40 | $928K | Form 4 |
| Jun 30, 2026 | Walid Abi-Saab | Chief Medical Officer | Sale plan | 10,000 | $46.46 | $465K | Form 4 |
| Jun 30, 2026 | Jack Kaye | Director | Sale plan | 17,060 | $46.43 | $792K | Form 4 |
| Jun 30, 2026 | Jack Kaye | Director | Sale plan | 4,107 | $46.49 | $191K | Form 4 |
| Jun 26, 2026 | Walid Abi-Saab | Chief Medical Officer | Sale | 1,434 | $46.86 | $67.2K | Form 4 |
| Jun 25, 2026 | Matthew C Kapusta | CEO | Sale plan | 28,716 | $50.02 | $1.4M | Form 4 |
| Jun 24, 2026 | Matthew C Kapusta | CEO | Sale plan | 6,696 | $50.00 | $335K | Form 4 |
| Jun 18, 2026 | Matthew C Kapusta | CEO | Sale plan | 37,015 | $50.00 | $1.9M | Form 4 |
| Jun 18, 2026 | Matthew C Kapusta | CEO | Sale plan | 4,656 | $50.00 | $233K | Form 4 |
| Jun 17, 2026 | Matthew C Kapusta | CEO | Sale plan | 32,581 | $45.02 | $1.5M | Form 4 |
| Jun 17, 2026 | Matthew C Kapusta | CEO | Sale plan | 11,585 | $48.65 | $564K | Form 4 |
| Jun 17, 2026 | Matthew C Kapusta | CEO | Sale plan | 33,334 | $45.01 | $1.5M | Form 4 |
| Jun 17, 2026 | Matthew C Kapusta | CEO | Sale plan | 23,977 | $42.61 | $1M | Form 4 |
| Jun 17, 2026 | Matthew C Kapusta | CEO | Sale plan | 6,023 | $43.70 | $263K | Form 4 |
| Jun 17, 2026 | Matthew C Kapusta | CEO | Sale plan | 56,929 | $43.43 | $2.5M | Form 4 |
| Jun 17, 2026 | Madhavan Balachandran | Director | Sale plan | 1,690 | $42.60 | $72K | Form 4 |
| Jun 17, 2026 | Madhavan Balachandran | Director | Sale plan | 4,700 | $43.66 | $205K | Form 4 |
| Jun 17, 2026 | Madhavan Balachandran | Director | Sale plan | 5,295 | $47.08 | $249K | Form 4 |
| Jun 17, 2026 | Jack Kaye | Director | Sale plan | 5,295 | $42.57 | $225K | Form 4 |
| Jun 15, 2026 | Madhavan Balachandran | Director | Sale plan | 10,000 | $27.85 | $278K | Form 4 |
| Jun 15, 2026 | Jeannette Potts | Chief Legal Officer | Sale | 5,237 | $27.67 | $145K | Form 4 |
| Jun 11, 2026 | David D. Meek | Director | Sale | 1,993 | $27.06 | $53.9K | Form 4 |
| Jun 11, 2026 | Robert Gut | Director | Sale plan | 2,726 | $27.06 | $73.8K | Form 4 |
| Jun 11, 2026 | Kylie O'Keefe | Chief Customer & Strat O | Sale | 15,936 | $27.06 | $431K | Form 4 |
| Jun 10, 2026 | Robert Gut | Director | Sale plan | 2,645 | $26.07 | $69K | Form 4 |
| Jun 10, 2026 | Robert Gut | Director | Sale plan | 3,127 | $26.03 | $81.4K | Form 4 |
| Jun 10, 2026 | Robert Gut | Director | Sale plan | 1,780 | $26.05 | $46.4K | Form 4 |
| Jun 3, 2026 | Jack Kaye | Director | Sale plan | 2,645 | $30.01 | $79.4K | Form 4 |
| May 8, 2026 | Walid Abi-Saab | Chief Medical Officer | Sale plan | 25,000 | $25.10 | $628K | Form 4 |
| May 8, 2026 | Walid Abi-Saab | Chief Medical Officer | Sale plan | 20,000 | $25.00 | $500K | Form 4 |
| Mar 4, 2026 | Matthew C Kapusta | CEO | Sale | 14,581 | $9.06 | $132K | Form 4 |
| Mar 4, 2026 | Walid Abi-Saab | Chief Medical Officer | Sale | 808 | $9.06 | $7.3K | Form 4 |
| Mar 4, 2026 | Jeannette Potts | Chief Legal Officer | Sale | 3,412 | $9.06 | $30.9K | Form 4 |
| Mar 4, 2026 | Christian Klemt | CFO | Sale | 12,000 | $9.06 | $109K | Form 4 |
| Mar 2, 2026 | Matthew C Kapusta | CEO | Sale | 34,437 | $9.95 | $343K | Form 4 |
| Mar 2, 2026 | Christian Klemt | CFO | Sale | 12,532 | $9.95 | $125K | Form 4 |
| Mar 2, 2026 | Jeannette Potts | Chief Legal Officer | Sale | 8,578 | $9.95 | $85.4K | Form 4 |
| Mar 2, 2026 | Walid Abi-Saab | Chief Medical Officer | Sale | 1,660 | $9.95 | $16.5K | Form 4 |
| Feb 25, 2026 | Matthew C Kapusta | CEO | Sale | 12,378 | $23.86 | $295K | Form 4 |
| Feb 25, 2026 | Christian Klemt | CFO | Sale | 6,217 | $23.86 | $148K | Form 4 |
| Jan 12, 2026 | Robert Gut | Director | Sale plan | 17,310 | $24.39 | $422K | Form 4 |
| Jan 12, 2026 | Robert Gut | Director | Sale plan | 7,803 | $25.09 | $196K | Form 4 |
| Jan 12, 2026 | Robert Gut | Director | Sale plan | 500 | $25.03 | $12.5K | Form 4 |
| Jan 9, 2026 | Jack Kaye | Director | Sale plan | 6,390 | $27.28 | $174K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Matthew C Kapusta | CEO, Managing Director, Director | – | $12.9M | Jul 2, 2026 |
| Walid Abi-Saab | Chief Medical Officer | – | $2.6M | Jun 30, 2026 |
| Jack Kaye | Director | – | $1.5M | Jun 30, 2026 |
| Robert Gut | Director | – | $901K | Jun 11, 2026 |
| Madhavan Balachandran | Director | – | $805K | Jun 17, 2026 |
| Kylie O'Keefe | Chief Customer & Strat Officer | – | $431K | Jun 11, 2026 |
| Christian Klemt | Chief Financial Officer | – | $382K | Mar 4, 2026 |
| Jeannette Potts | Chief Legal Officer | – | $261K | Jun 15, 2026 |
| David D. Meek | Director | – | $247K | Nov 6, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
QURE short interest
High short interest. 12.3% of QURE shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went down 17%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 8.51M QURE shares were sold short, 12.3% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 6.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 8.51M | 12.26% | -3% | 1.33M | 6.4 |
| Oct 15, 2026 | 8.73M | 12.58% | +0% | 2.27M | 3.8 |
| Sep 30, 2026 | 8.72M | 12.56% | -12% | 4.49M | 1.9 |
| Sep 15, 2026 | 9.92M | 14.30% | +0% | 1.22M | 8.1 |
| Aug 31, 2026 | 9.87M | 14.24% | -8% | 1.05M | 9.4 |
| Aug 14, 2026 | 10.77M | 15.53% | +1% | 1.09M | 9.8 |
| Jul 31, 2026 | 10.68M | 15.40% | +3% | 1.57M | 6.8 |
| Jul 15, 2026 | 10.37M | 16.44% | -10% | 1.46M | 7.1 |
| Jun 30, 2026 | 11.49M | 18.23% | -3% | 4.47M | 2.6 |
| Jun 15, 2026 | 11.81M | 18.72% | +6% | 1.44M | 8.2 |
| May 29, 2026 | 11.10M | 17.60% | +8% | 1.23M | 9.0 |
| May 15, 2026 | 10.30M | 16.33% | -5% | 2.57M | 4.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
uniQure company events
uniQure filed 15 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Nov 2, 2026AnnouncementThe Company announced the FDA has accepted for review the BLA for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. Filing
- Sep 29, 2026AnnouncementShared information with investors. Filing
- Sep 2, 2026AnnouncementShared information with investors. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jun 24, 2026AgreementUniQure N.V. entered into an underwriting agreement with Leerink Partners LLC, as representative of the several underwriters named therein, relating to an underwritten public offering of 4,945,055 of the Company’s ordinary shares, at a price to the public of $ 45.50 per ordinary share. Filing
- Jun 22, 2026AnnouncementThe Company announced preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. Filing
- Jun 17, 2026AnnouncementUniQure N.V. issued a press release announcing its plan to submit its Biologic License Application for AMT-130 in Huntington’s Disease during the third quarter of 2026. Filing
- Jun 15, 2026LeadershipAs described in Item 5.07, on June 10, 2026, at the 2026 Annual General Meeting of Shareholders, the shareholders of uniQure N.V. approved an amendment to the Company’s Amended and Restated 2014 Share Incentive Plan to increase the number of ordinary shares reserved for issuance thereunder. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Apr 30, 2026AnnouncementShared information with investors. Filing
- Mar 2, 2026ResultsReleased financial results. Filing
- Jan 13, 2026AnnouncementShared information with investors. Filing
- Jan 9, 2026AnnouncementShared information with investors. Filing
- Dec 4, 2025AnnouncementThe Company announced that the Company received final meeting minutes from the U.S. Food and Drug Administration regarding a pre-Biologics License Application meeting held on October 29, 2025 to discuss the application for AMT-130, an investigational gene therapy for Huntington’s disease. In the… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
uniQure financials
Famous investors that hold QURE
4 of the 50 well-known investors we track reported holding QURE in their latest 13F filing. The largest position is Ken Griffin's, worth $17.4M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 718,875 | $17.4M | 0.0% | -21% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 330,665 | $8M | 0.0% | -45% |
| Israel Englander · Millennium Management | Q3 2026 | 181,618 | $4.4M | 0.0% | -47% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 99,263 | $2.4M | 0.0% | -70% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named QURE in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Oct 16, 2026 | JPMORGAN CHASE & CO. | 13G/A | 8.5% |
| Oct 16, 2026 | JPMORGAN CHASE & CO. | 13G/A | 8.5% |
Questions about uniQure N.V. (QURE) stock
Who owns the most QURE stock?
The largest reported owner of uniQure N.V. (QURE) is Avoro Capital Advisors LLC, with 10.7% of the company. In total, 255 funds and institutions reported holding QURE at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are QURE insiders buying or selling?
In the last 12 months, QURE insiders reported no open-market purchases and 48 sales worth $20M. The latest trade was on Nov 6, 2026. See every trade.
What is the short interest in QURE?
As of Oct 30, 2026, 8.51M QURE shares were sold short, 12.3% of the shares outstanding, down 2.5% from the report before. At the average daily volume of 1.33M shares, buying them all back would take about 6.4 trading days (days to cover). See the history.
Which famous investors hold QURE?
4 of the 50 well-known investors we track reported QURE in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $17.4M. See all holders.
Executive pay
uniQure's chief executive was paid a total of $3.3M for the year ended Dec 31, 2025, up 7% from $3.1M the year before. In the last 12 months, uniQure's executives and directors bought no stock on the open market and sold $20M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.